This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignees: Institut Pasteur De Lille, National Institute of Health and Medical Research, Université De Lille. Active years: 2026.
Company Filing History:
1 out of 65 
1 out of 1,853 
1 out of 65 
Years Active: 2026
Title: Damien Bosc: Innovator in ERAP Inhibitors
Introduction
Damien Bosc is a notable inventor based in Haubourdin, France. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit endoplasmic reticulum aminopeptidases (ERAP). His work is crucial for advancing therapeutic options for various disorders.
Latest Patents
Damien Bosc holds 1 patent related to ERAP inhibitors. The patent discloses novel compounds of formula (I) that are useful as inhibitors of ERAP, specifically targeting ERAP2. These compounds have potential therapeutic applications in treating or preventing proliferative disorders, autoinflammatory disorders, and autoimmune disorders.
Career Highlights
Throughout his career, Damien has worked with esteemed institutions such as Université de Lille and Institut Pasteur de Lille. His research has focused on the biochemical pathways involved in immune responses and the development of innovative therapeutic strategies.
Collaborations
Damien has collaborated with notable colleagues, including Benoit Deprez and Valentin Guillaume. Their combined expertise has contributed to the advancement of research in the field of aminopeptidase inhibitors.
Conclusion
Damien Bosc's innovative work in the development of ERAP inhibitors showcases his commitment to advancing medical science. His contributions are paving the way for new treatments for complex disorders.